Despite successes, thus far, the overall response rate was 57% in PD-L1 positive patients.8 It is becoming a pressing necessity to identify additional biomarker predicting respond to ICIs in melanoma with PD-L1 expression and clarify the mechanism. This evidence concerns the gene CD274 and melanoma.